KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Return on Capital Employed (2019 - 2025)

Vir Biotechnology's Return on Capital Employed history spans 7 years, with the latest figure at 52.2% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 801.0% to 52.2% in Q4 2025 year-over-year; TTM through Dec 2025 was 52.2%, a 801.0% decrease, with the full-year FY2025 number at 43.26%, down 511.0% from a year prior.
  • Return on Capital Employed hit 52.2% in Q4 2025 for Vir Biotechnology, up from 53.22% in the prior quarter.
  • Over the last five years, Return on Capital Employed for VIR hit a ceiling of 92.72% in Q1 2022 and a floor of 57.61% in Q1 2021.
  • Historically, Return on Capital Employed has averaged 14.92% across 5 years, with a median of 34.83% in 2023.
  • Biggest five-year swings in Return on Capital Employed: soared 15032bps in 2022 and later crashed -10713bps in 2023.
  • Tracing VIR's Return on Capital Employed over 5 years: stood at 33.9% in 2021, then rose by 10bps to 37.22% in 2022, then crashed by -202bps to 37.88% in 2023, then decreased by -17bps to 44.18% in 2024, then dropped by -18bps to 52.2% in 2025.
  • Business Quant data shows Return on Capital Employed for VIR at 52.2% in Q4 2025, 53.22% in Q3 2025, and 52.96% in Q2 2025.